IgA1 HR has up to 6 of the 9 potential O-glycosylation sites occupied; some Gal-deficient glycans consist of terminal N-acetylgalactosamine (GalNAc). IgA1 HR O-glycosylation was reported

to be initiated by GalNAc-T2. However, the expression of GalNAc-T2 does not differ between cells from patients and those from healthy controls (HC). In contrast, expression of GalNAc-T14, the enzyme with highest similarity to GalNAc-T2, is 5-fold greater in IgA1-producing cells derived from IgAN patients than in those from HC. Here, we analyzed kinetics and site-specificities of GalNAc-T2 and -T14 on HR using high-resolution mass spectrometry (MS). Methods: We produced recombinant soluble GalNAc-T2 and -T14 enzymes. A synthetic HR peptide (sHR) and a panel of synthetic Selleckchem JQ1 HR glycopeptides (sGP) with a single GalNAc residue at different sites were used as acceptors.

Results: GalNAc-T2 showed higher activity i.e., faster rate of glycosylation of sHR, than did GalNAc-T14. Up to 8 sites were glycosylated in sHR by GalNAc-T2, whereas GalNAc-T14 added GalNAc to up to 5 sites in HR of IgA1. Distinct sHR O-glycoforms generated by GalNAc-T2 and -T14 were subjected to tandem MS to localize glycosylated sites. The sites of glycosylation on sHR catalyzed by GalNAc-T2 and -T14 were the same for the variants with up to 5 sites and BGB324 order appeared predominantly in an ordered fashion: GalNAc was attached to T7 first and then to T15, followed by S11 and T4. Localization of GalNAc on sGP did not affect kinetics of the GalNAc-T2. GalNAc-T14 effectively glycosylated sGP variant with a GalNAc at S9, the site that corresponds to S230 on IgA1 HR, the dominant site with terminal GalNAc in Gd-IgA1 proteins. GalNAc-T2 and -T14 have similar site-specificity on IgA1 HR, but differ in kinetics and how they are affected by preexisting glycosylation. Conclusion: Elevated

expression of a specific GalNAc-T is a possible mechanism Gemcitabine order for production of Gd-IgA1 in IgAN. TAKAHASHI KAZUO1,2, RASKA MILAN1,3, STEWART TYLER J.1, STUCHLOVA HORYNOVA MILADA1,3, VRABLIKOVA ALENA1,3, HALL STACY D.1, HIKI YOSHIYUKI4, YUZAWA YUKIO2, MOLDOVEANU ZINA1, JULIAN BRUCE A.1, RENFROW MATTHEW B.1, NOVAK JAN1 1University of Alabama at Birmingham; 2Fujita Health University School of Medicine; 3Palacky University in Olomouc; 4Fujita Health University School of Health Sciences Introduction: Patients with IgAN have elevated serum levels of galactose (Gal)-deficient IgA1; some hinge-region (HR) O-glycans consist of terminal N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc, sialic acid). Sialylation of GalNAc blocks subsequent galactosylation. IgA1-producing cells from IgAN patients have increased activity of α2,6-sialyltransferase (ST6GalNAc) that sialylates GalNAc.